好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Supervised Insole Gait Analysis in MS Clinical Practice: A Cost-effective Alternative
Multiple Sclerosis
P10 - Poster Session 10 (8:00 AM-9:00 AM)
19-010

To evaluate the validity of in-clinic standardized mobility assessments in people with multiple sclerosis (pwMS) using a smart insole-based system (Insole).

Objectively assessing mobility in pwMS is essential for clinical evaluation and timely rehabilitation. However, conventional instrumented gait analysis demands costly, space-intensive equipment and specialized staff, limiting routine use in MS centres. Supervised, Insole–based methods may provide a low-cost, clinic-ready alternative.

Fifty-two pwMS completed the Timed 25-Foot Walk (T25FW) and the 2-Minute Walk Test (2MWT); forty-six pwMS also performed four jump assessments on force plates (FP; 10-Second Hop Test, Countermovement Jump, Single-leg Countermovement Jump right/left). An independent cohort of 18 healthy participants performed jump tasks. All activities were supervised and were conducted under a standardized clinical workflow aligned with the Dresden Protocol for Multidimensional Walking Assessment, which operationalizes routine, clinic-feasible gait assessments in MS.

For every task, participants wore Insoles that streamed raw plantar pressure, accelerometer, and gyroscope data to a smartphone application (Celestra Health Systems, Canada). Custom algorithms recognized ambulatory activities, computed clinical endpoints (2MWT distance; T25FW time), and derived spatiotemporal features (68 walking- and 74 turning-related metrics). Clinical endpoints were compared against ground truth (wheel odometer for 2MWT, photoelectric timing gate for T25FW). For all jumping tasks, 17 temporal, kinematic, and kinetic parameters were compared against FP-based measures.

In the 2MWT, average absolute distance from the odometer was 4.4 m (2.7%). In the T25FW, average absolute time difference was 0.2 s (4.0%). FP agreement (ICC(3,k)) was ≥0.75 for 15 of 17 metrics across all jumping activities. Walking and turning comparisons will be presented at the conference.

Insole-derived measures were comparable to references and fell within minimum detectable change thresholds, while providing richer spatiotemporal and turning insights. Given the small deviations (<5%), this supervised, insole-based system appears suitable for objective mobility assessments in neurorehabilitation and MS outpatient care.

Authors/Disclosures
Matthew P. Mavor, PhD
PRESENTER
Dr. Mavor has or had stock in Celestra Health Systems.Dr. Mavor has received research support from the Government of Canada. Dr. Mavor has received intellectual property interests from a discovery or technology relating to health care.
Eric Chan, DO Dr. Chan has nothing to disclose.
Mohammad H. Akhavanfar, PhD Dr. Akhavanfar has stock in Shopify. Dr. Akhavanfar has stock in Nvidia.
Heidi Stölzer-Hutsch Mrs. Stölzer-Hutsch has nothing to disclose.
Katrin Trentzsch, PT Mrs. Trentzsch has nothing to disclose.
Tjalf Ziemssen, MD, FAAN (University Clinic Dresden) Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS . Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dresden Internation University. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from BMS. The institution of Dr. Ziemssen has received research support from Roche.
Ryan Graham, PhD Dr. Graham has stock in Celestra Health Systems. The institution of Dr. Graham has received research support from Government of Canada. The institution of Dr. Graham has received research support from Government of Ontario. The institution of Dr. Graham has received research support from MITACS. The institution of Dr. Graham has received research support from Ontario Centre for Innovation. Dr. Graham has received intellectual property interests from a discovery or technology relating to health care.